Intercell to Webcast Research & Development Day on Thursday, June 4, 2009

VIENNA and GAITHERSBURG, Md., May 27 /PRNewswire/ -- Intercell AG (VSE: ICLL)
today announced that it will webcast its Research & Development Day being held
in New York on Thursday, June 4 starting at 12:00 p.m. Eastern Time (6 pm CET,
5 pm GMT).

"This year's meeting will focus on the applications we are pursuing with our
novel, needle-free vaccine patch technology," said Gerd Zettlmeissl, Chief
Executive Officer of Intercell. "Our proprietary vaccine technology platforms
have yielded a rich pipeline of products and enabled us to partner with
leading pharmaceutical companies. We also look forward to providing an update
on the launch of IXIARO(R), our novel vaccine to prevent Japanese
Encephalitis, as well as our other partnered programs."

The featured speaker at the meeting is Dr. Herbert DuPont, a specialist in
infectious disease and the primary investigator for the Intercell Travelers'
Diarrhea Phase II clinical trial. Dr. Dupont will discuss the need for new
vaccines particularly for travelers. Dr. DuPont currently serves as director
for the Center for Infectious Diseases at The University of Texas Health
Science Center, School of Public Health. He also holds positions as the chief
of internal medicine at St. Luke's Episcopal Hospital in Houston and the
Baylor College of Medicine H. Irving Schweppe, Jr., MD, chair in internal
medicine. Dr. DuPont has been a director of the National Foundation of
Infectious Diseases since 1981 and a vice president of the Foundation for the
past three years.

In addition to Dr. DuPont, members of the Intercell management team will make
presentations including, Gerd Zettlmeissl, Chief Executive Officer of
Intercell AG, Thomas Lingelbach, Chief Operating Officer of Intercell AG,
Reinhard Kandera, Chief Financial Officer of Intercell AG, Alexander von
Gabain, Chief Scientific Officer of Intercell AG and Gregory M. Glenn, Chief
Scientific Officer of Intercell USA.

Webcast Details
The slide and audio presentation will be available live from the investor
relations section of the company's website at www.intercell.com. To ensure a
timely connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled webcast (in addition, the webcast will
be archived on www.intercell.com).

Agenda

-- Introduction & Strategic Overview
Gerd Zettlmeissl, CEO Intercell AG

-- Travelers' Diarrhea: Vaccination and the importance of prevention
Prof. Herbert DuPont, Guest speaker
Professor and Director of the Center for Infectious Diseases,
University of Texas, School of Public Health

-- Intercell's Vaccine Patch Technology
Gregory M. Glenn, CSO Intercell USA, Inc.

-- Business Update
Thomas Lingelbach, COO Intercell AG

-- Scientific Update
Alexander von Gabain, CSO Intercell AG

-- Financial Update & Outlook
Reinhard Kandera, CFO Intercell AG

About Intercell AG
Intercell AG is an innovative biotechnology company that develops novel
vaccines for the prevention and treatment of infectious diseases with
substantial unmet medical needs. Intercell's vaccine to prevent Japanese
Encephalitis is the Company's first product on the market.

The Company's technology platforms include an antigen-discovery system,
adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine
Enhancement Patch). Based on these technologies, Intercell has strategic
partnerships with a number of global pharmaceutical companies, including
Novartis, Merck & Co., Inc., Wyeth, and Sanofi Pasteur.

The Company's pipeline includes a Travelers' Diarrhea Vaccine Patch (Phase II
concluded), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement
Patch to prevent Pandemic Influenza in combination with an injected vaccine, a
vaccine program for S. aureus, which is being developed with Merck & Co., Inc.
(Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In
addition, three other products focused on infectious diseases are in
pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S.
level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking
statements concerning Intercell AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Intercell AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a
result of new information, future events or otherwise.

SOURCE Intercell AG

Lucia Malfent, Head of Corporate Communications of Intercell AG,
+43-1-20620-1303, LMalfent@intercell.com